Biofortis and ProDigest unite to strengthen gut research service range

By Will Chu

- Last updated on GMT

©Biofortis Mérieux NutriSciences
©Biofortis Mérieux NutriSciences

Related tags ProDigest Biofortis microbiome

ProDigest and Biofortis are to enter into an agreement to strengthen and enlarge their service offerings that currently includes microbiome research and probiotic and botanical extract efficacy.

The agreement aims to specifically combine the preclinical testing capabilities of ProDigest with the expertise in clinical trials and microbiome analysis of Contract Research Organisation (CRO) Biofortis.

“We are pleased to collaborate with our colleagues at ProDigest to facilitate and accelerate the development of the future drugs and products in the field of gastrointestinal research,”​ says Etienne Casal, senior vice-president Europe of Mérieux NutriSciences, Biofortis’ parent company.

“This collaboration will also stimulate innovation by sharing R&D projects,” ​adds Benoit Fouchaq, managing director of Biofortis.

Ghent uni spin-off

Founded in 2008, ProDigest is a spin-off from the Laboratory of Microbial Ecology and Technology (LabMET), located at Ghent university (Belgium).

Specialising in gastrointestinal research, the firm now offers its own in vitro​ technology platform, developed at LabMET, which is organized round a dynamic simulation model of the gastrointestinal tract.

The model, Simulator of the Human Intestinal Microbial Ecosystem (SHIME), essentially recreates the physiology and microbiology of the entire gastrointestinal tract as well as generate insights into mechanisms of action of prebiotics, probiotics or drugs in different gastrointestinal areas.

“We are excited about this opportunity,”​ says Massimo Marzorati, CEO of ProDigest. “The research area around the human gut is rapidly evolving as witnessed by the requests we receive from our clients around the world.

‘Innovative supply chain’

“The collaboration with Biofortis will create an innovative supply chain in which in vitro and in vivo data will be merged to provide a unique insight on the efficacy and functionality of new actives in the food and pharma market.”

Similarly, Biofortis specialise in designing and running of experimental, pre-clinical sample analysis and clinical research projects, since 2002.

Its nutrition and microbiome analytical service includes the use of internal clinical investigation centres and central lab capabilities, that complement its knowhow in sample collection, analytical processes, biostatistics and other metagenomics services.

The CRO’s parent company, Mérieux NutriSciences, welcomed Nicolas Cartier as its new CEO on 1 October having been appointed as the firm’s COO in May 2020.

Related news

Related products

show more

Whitepaper: Discover a new era in postbiotics

Whitepaper: Discover a new era in postbiotics

Content provided by DSM Nutritional Products | 28-Nov-2023 | White Paper

Postbiotic ingredients are set to open up a world of opportunities across the human health and nutrition industry, fueled by developing science demonstrating...

Taking Immune Support to a New Level

Taking Immune Support to a New Level

Content provided by AB Biotek Human Nutrition & Health | 30-Oct-2023 | White Paper

Patent-pending ABB C1® redefines immune support by addressing innate, acquired, and Trained Immunity. In 'ABB C1®: Training Now for Future Immune...

Custom Biotic Solutions for Digestive Health

Custom Biotic Solutions for Digestive Health

Content provided by ADM: Innovation that Feeds the Future | 10-Oct-2023 | White Paper

A growing body of evidence shows gut health can affect digestive health, well-being, and many health areas in between.

Related suppliers

Follow us


View more